Teva Pharmaceutical Industries Restricted (TEVA) Q2 2026 Earnings Name Transcript
Teva Pharmaceutical Industries Restricted (TEVA) Q2 2026 Earnings Name July 29, 2026 8:00 AM EDT
Firm Members
Christopher Stevo – Senior Vice President of Investor Relations & Aggressive Intelligence
Richard Francis – President, CEO & Director
Eric Hughes – Govt VP of International R&D and Chief Medical Officer
Eliyahu Kalif – Govt VP & CFO
Convention Name Members
Jason Gerberry – BofA Securities, Analysis Division
Umer Raffat – Evercore ISI Institutional Equities, Analysis Division
Louise Chen – Scotiabank International Banking and Markets, Analysis Division
Yuchen Ding – Jefferies LLC, Analysis Division
David Amsellem – Piper Sandler & Co., Analysis Division
Ashwani Verma – UBS Funding Financial institution, Analysis Division
Glen Santangelo – Barclays Financial institution PLC, Analysis Division
Matthew Dellatorre – Goldman Sachs Group, Inc., Analysis Division
Presentation
Operator
Hi there all people, and welcome to the Q2 2026 Teva Pharmaceutical Industries Earnings Convention Name. My identify is Elliot. I will be coordinating your name at the moment. [Operator Instructions] I’d now like handy over to Christopher Stevo.
Christopher Stevo
Senior Vice President of Investor Relations & Aggressive Intelligence
Thanks, Elliot. Good morning and good afternoon, everybody. Thanks for becoming a member of us on our second quarter name. Clearly, our supplies are posted to our web site this morning, so please see these. And earlier than I flip the decision over to our CEO, Richard Francis, I would prefer to remind everybody that we’ll be making forward-looking statements on this name. The corporate cautions traders that any forward-looking assertion includes dangers and uncertainties and isn’t a assure of future efficiency.
Precise outcomes could differ materially from these expressed or implied within the forward-looking statements resulting from a wide range of components. These components are described in our earnings press launch and our most up-to-date Kinds 10-Q and 10-Okay filed with the SEC. Any statements that we make are solely as of at the moment, we undertake no obligation to replace these
